Trevi Therapeutics, Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing reveals a company at a critical inflection point, balancing a strong clinical signal against a high-burn financial model. The successful April 2026 offering at $13.00 per share demonstrates strong institutional support and provides the necessary fuel for the upcoming Phase 3 trials. However, the widening net loss to $13.2 million highlights the inherent costs of advancing a drug candidate through the most expensive stages of development. Ultimately, the investment thesis now shifts from a question of survival to a question of clinical execution. With a fortified balance sheet, the primary catalyst is no longer the ability to raise money, but the ability to successfully navigate the pivotal trials for IPF and RCC. Investors must weigh the high potential reward of a first-in-class chronic cough therapy against the binary risk of Phase 3 outcomes and the potential for long-term warrant dilution.